Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Incorporating Assessments Of Sequence-Dependence In Developmental Studies Of Combination Chemotherapy Regimens Containing New Agents And Platinum Compounds

E. K. Rowinsky
Published 1996 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The evaluation of combination chemotherapy regimens that incorporate new drugs has been accepted as the next rationale step in the development of new cytotoxic agents following the completion of phase I and early phase II trials. Before incorporating new agents into combination chemotherapy regimens, the new agent should have demonstrated a sufficient level of antitumor activity in relevant tumor types. In addition, adequate preclinical and clinical information about optimal scheduling should be available. New cytotoxic agents are often combined with platinum compounds, such as cisplatin and carboplatin, if the new agents possess relevant antitumor activity in ovarian, non-small and small cell lung, bladder, and germ cell carcinomas, as well as in other malignancies in which the platinum compounds are the mainstay of therapy.
This paper references
Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II).
B. Drewinko (1976)
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
E. Rowinsky (1988)
Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.
G. Sledge (1994)
Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8.
C. Benz (1981)
The effect of vincristine on methotrexate uptake and inhibition of DNA synthesis by human lymphoblastoid cells.
R. Warren (1977)
Combination chemotherapy in vitro. III. BCNU.
B. Drewinko (1979)
Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats.
G. LeBlanc (1992)
Optimal Scheduling of Methotrexate and 5-Fluorouracil in Human Breast Cancer
C. Benz (1982)
Combination chemotherapy with Taxol (paclitaxel) in metastatic breast cancer.
Holmes Fa (1994)
Inhibition of p34cdc2 kinase activation, p34cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide.
R. Lock (1992)
10.1200/JCO.1992.10.4.520
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
D. Jodrell (1992)
The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia.
R. F. Zager (1973)
10.1200/JCO.1989.7.11.1748
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
A. Calvert (1989)
Lack of therapeutic synergism between vincristine and methotrexate in L1210 murine leukemia in vivo.
R. Bender (1978)
Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells.
R. J. Parker (1993)
10.1002/IJC.2910500420
Effects of CPT‐11 in combination with other anti‐cancer agents in culture
Y. Kano (1992)
Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response.
C. Benz (1985)
10.1200/JCO.1995.13.11.2688
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
10.1016/0006-2952(91)90729-O
Sequence-dependent interaction of 5-fluorouracil and arabinosyl-5-azacytosine or 1-beta-D-arabinofuranosylcytosine.
J. Grem (1991)
10.1200/JCO.1984.2.4.311
Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate.
N. Kemeny (1984)
10.1093/OXFORDJOURNALS.ANNONC.A058082
Is interferon-a an active agent in Castleman's disease?
N. Pavlidis (1992)
10.1016/0277-5379(90)90127-F
Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells.
E. Katz (1990)
10.1016/0065-2571(84)90007-4
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.
T. Chou (1984)
10.1126/SCIENCE.472732
Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism.
E. Cadman (1979)
10.1200/JCO.1991.9.9.1692
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
E. Rowinsky (1991)
Alteration of methotrexate uptake in human leukemia cells by other agents.
R. Bender (1975)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar